Komleva, Y.K.; Potapenko, I.V.; Lopatina, O.L.; Gorina, Y.V.; Chernykh, A.; Khilazheva, E.D.; Salmina, A.B.; Shuvaev, A.N.
NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer’s Disease. Int. J. Mol. Sci. 2021, 22, 11588.
https://doi.org/10.3390/ijms222111588
AMA Style
Komleva YK, Potapenko IV, Lopatina OL, Gorina YV, Chernykh A, Khilazheva ED, Salmina AB, Shuvaev AN.
NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer’s Disease. International Journal of Molecular Sciences. 2021; 22(21):11588.
https://doi.org/10.3390/ijms222111588
Chicago/Turabian Style
Komleva, Yulia K., Ilia V. Potapenko, Olga L. Lopatina, Yana V. Gorina, Anatoly Chernykh, Elena D. Khilazheva, Alla B. Salmina, and Anton N. Shuvaev.
2021. "NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer’s Disease" International Journal of Molecular Sciences 22, no. 21: 11588.
https://doi.org/10.3390/ijms222111588
APA Style
Komleva, Y. K., Potapenko, I. V., Lopatina, O. L., Gorina, Y. V., Chernykh, A., Khilazheva, E. D., Salmina, A. B., & Shuvaev, A. N.
(2021). NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer’s Disease. International Journal of Molecular Sciences, 22(21), 11588.
https://doi.org/10.3390/ijms222111588
